ICIs

DRUG2 trials

Sponsors

First Affiliated Hospital of Wenzhou Medical University, The First People's Hospital of Neijiang

Conditions

AKI Incidence of Cancer Patients Receiving AntiVEGF or ICIsHCCTherapy Adverse Effect

Unknown Phase

Acute Kidney Injury in Cancer Patients Receiving Anti-Vascular Endothelial Growth Factor Monoclonal Antibody vs Immune Checkpoint Inhibitors

CompletedNCT06119347

First Affiliated Hospital of Wenzhou Medical UniversityAKI Incidence of Cancer Patients Receiving AntiVEGF or ICIs

Start: 2020-01-01End: 2023-10-10Updated: 2023-11-08

ICIs With and Without MWA in Advanced Hepatocellular Carcinoma

CompletedNCT06581497

The First People's Hospital of NeijiangHCC, Therapy Adverse Effect

Start: 2022-01-01End: 2026-01-01Updated: 2026-01-14

Related Papers

Acute kidney injury in cancer patients receiving anti-vascular endothelial growth factor monoclonal antibody vs. immune checkpoint inhibitors: a retrospective real-world study

BMC Cancer2024-06-24